fingolimod hydrochloride has been researched along with Alloxan Diabetes in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 5 (23.81) | 29.6817 |
| 2010's | 12 (57.14) | 24.3611 |
| 2020's | 3 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Fernandes, V; Khatri, DK; Khot, M; Preeti, K; Singh, SB; Sood, A | 1 |
| Fernandes, V; Khatri, DK; Preeti, K; Singh, SB; Sood, A | 1 |
| Jin, Z; Sun, M; Weng, H; Ye, H; Yuan, Y | 1 |
| Buchwald, P; Frei, AW; Jiang, K; Li, Y; Stabler, CL | 1 |
| Hu, S; Jin, Y; Ni, H; Xu, H; Zhang, Q | 1 |
| Rana, A; Sharma, S | 1 |
| Gao, Q; Jiang, Z; Liu, R; Lu, B; Ren, M; Wu, Y; Zhou, Y | 1 |
| Fan, L; Yan, H | 1 |
| Abdullah, CS; Jin, ZQ; Li, Z; Wang, X | 1 |
| Chen, Z; Cui, K; Liu, J; Rao, K; Ruan, Y; Wang, S; Wang, T | 1 |
| Botchwey, EA; Bowers, DT; Brayman, KL; Chhabra, P; Langman, L; Lin, D; Linhart, RS; Merrill, PH; Olingy, CE; Tanes, ML | 1 |
| Arndt, T; Hedrich, HJ; Jörns, A; Lenzen, S; Meyer Zu Vilsendorf, A; Rath, KJ; Terbish, T; Wedekind, D | 1 |
| Awad, AS; Bolton, WK; Huang, L; Khutsishvili, K; Lynch, KR; Okusa, MD; Rouse, MD | 1 |
| Bromberg, JS; Ding, Y; Shi, Q; Xu, J; Yin, N; Zhang, N | 1 |
| Botchwey, EA; Bowers, DT; Brayman, KL; Chhabra, P; Langman, L | 1 |
| Bennet, W; Goto, M; Groth, CG; Korsgren, O; Maeda, A; Wennberg, L; Zhang, J | 1 |
| Cottens, S; Hering, BJ; Kenyon, NM; Kenyon, NS; Kirchhof, N; Lake, P; Mullon, C; Ricordi, C; Wijkstrom, M | 1 |
| Bi, Y; He, X; Liu, L; Shang, W; Wang, C; Wang, D | 1 |
| Amemiya, H; Funeshima, N; Kawabe, A; Kazui, T; Li, XK; Suzuki, K; Suzuki, S | 1 |
| Brinkmann, V; Hengartner, H; Ochsenbein, AF; Odermatt, B; Pinschewer, DD; Zinkernagel, RM | 1 |
| Brinkmann, V; Deleo, J; Fu, F; Hoover, J; Hopf, C; Hu, S; Lake, P; Li, S; Shi, VC; Wang, S | 1 |
21 other study(ies) available for fingolimod hydrochloride and Alloxan Diabetes
| Article | Year |
|---|---|
Fingolimod Alleviates Cognitive Deficit in Type 2 Diabetes by Promoting Microglial M2 Polarization via the pSTAT3-jmjd3 Axis.
Topics: Animals; Cell Polarity; Cognition; Cognitive Dysfunction; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fingolimod Hydrochloride; Mice; Microglia; Neuroinflammatory Diseases; Signal Transduction | 2023 |
Sphingosine 1 phosphate lyase inhibition rescues cognition in diabetic mice by promoting anti-inflammatory microglia.
Topics: Animals; Apoptosis Regulatory Proteins; Cognition; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fingolimod Hydrochloride; Mice; Microglia; Neuroinflammatory Diseases; Phosphates; Phosphoric Monoester Hydrolases; Sphingosine; Tumor Suppressor Protein p53 | 2023 |
FTY-720 alleviates diabetes-induced liver injury by inhibiting oxidative stress and inflammation.
Topics: Animals; Chemical and Drug Induced Liver Injury, Chronic; Diabetes Mellitus, Experimental; Fingolimod Hydrochloride; Glucose; Inflammation; Liver; Mice; NF-kappa B; Oxidative Stress; Toll-Like Receptor 4 | 2023 |
Local delivery of fingolimod from three-dimensional scaffolds impacts islet graft efficacy and microenvironment in a murine diabetic model.
Topics: Animals; Cellular Microenvironment; Diabetes Mellitus, Experimental; Disease Models, Animal; Drug Delivery Systems; Fingolimod Hydrochloride; Islets of Langerhans Transplantation; Male; Mice, Inbred C57BL; Time Factors; Tissue Scaffolds | 2018 |
Sphingosine-1-phosphate receptor agonist, FTY720, restores coronary flow reserve in diabetic rats.
Topics: Ammonia; Animals; Blood Glucose; Capillaries; Cell Adhesion Molecules; Collagen; Coronary Circulation; Coronary Disease; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Drug Evaluation, Preclinical; Fingolimod Hydrochloride; Gene Expression Regulation; Interleukin-6; Lysophospholipids; Male; Microcirculation; Myocardium; Nitrogen Radioisotopes; Positron-Emission Tomography; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Sphingosine; Transforming Growth Factor beta | 2014 |
Mechanism of sphingosine-1-phosphate induced cardioprotection against I/R injury in diabetic rat heart: Possible involvement of glycogen synthase kinase 3β and mitochondrial permeability transition pore.
Topics: Animals; Blood Glucose; Cardiotonic Agents; Creatine Kinase, MB Form; Diabetes Mellitus, Experimental; Diet, High-Fat; Fingolimod Hydrochloride; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Ischemic Preconditioning; Lipids; Lysophospholipids; Male; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Myocardial Reperfusion Injury; Myocardium; Rats; Rats, Wistar; Sphingosine | 2016 |
Effect of a new drug releasing system on microencapsulated islet transplantation.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Disease Models, Animal; Drug Carriers; Fingolimod Hydrochloride; Flow Cytometry; Graft Survival; Graphite; Immunohistochemistry; Immunosuppressive Agents; Islets of Langerhans Transplantation; Lymphocyte Count; Male; Rats; Rats, Sprague-Dawley; Rats, Wistar; T-Lymphocytes; Transplantation, Heterologous | 2015 |
FTY720 Attenuates Retinal Inflammation and Protects Blood-Retinal Barrier in Diabetic Rats.
Topics: Administration, Oral; Animals; Blood-Retinal Barrier; Blotting, Western; Diabetes Mellitus, Experimental; Disease Progression; Down-Regulation; Fingolimod Hydrochloride; Immunohistochemistry; Immunosuppressive Agents; Male; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Receptors, Lysosphingolipid; Retinitis; RNA | 2016 |
Depletion of T lymphocytes ameliorates cardiac fibrosis in streptozotocin-induced diabetic cardiomyopathy.
Topics: Animals; Antigens, CD34; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Fibrosis; Fingolimod Hydrochloride; Homeodomain Proteins; Lymphocyte Depletion; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardium; T-Lymphocytes; Transforming Growth Factor beta1 | 2016 |
FTY720 Supplementation Partially Improves Erectile Dysfunction in Rats With Streptozotocin-Induced Type 1 Diabetes Through Inhibition of Endothelial Dysfunction and Corporal Fibrosis.
Topics: Animals; Diabetes Mellitus, Experimental; Disease Models, Animal; Erectile Dysfunction; Fibrosis; Fingolimod Hydrochloride; Male; Penile Erection; Random Allocation; Rats; Rats, Sprague-Dawley; Streptozocin | 2017 |
An engineered macroencapsulation membrane releasing FTY720 to precondition pancreatic islet transplantation.
Topics: Animals; Cell Survival; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Humans; Islets of Langerhans; Islets of Langerhans Transplantation; Membranes, Artificial; Mice; Mice, Inbred C57BL; Mice, Knockout; Nanofibers; Polyesters; Polylactic Acid-Polyglycolic Acid Copolymer; Streptozocin | 2018 |
Diabetes prevention by immunomodulatory FTY720 treatment in the LEW.1AR1-iddm rat despite immune cell activation.
Topics: Animals; CD8 Antigens; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Drug Evaluation, Preclinical; Female; Fingolimod Hydrochloride; Gene Expression Regulation; Immune System; Immunomodulation; Immunosuppressive Agents; Lymph Nodes; Lymphocyte Activation; Male; Pancreas; Propylene Glycols; Rats; Sphingosine | 2010 |
Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes.
Topics: Animals; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fingolimod Hydrochloride; Kidney; Lymphocytes; Mice; Mice, Inbred C57BL; Oxadiazoles; Phosphotransferases (Alcohol Group Acceptor); Podocytes; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Sphingosine; Thiophenes; Tumor Necrosis Factor-alpha | 2011 |
Targeting lymphangiogenesis after islet transplantation prolongs islet allograft survival.
Topics: Animals; Antibodies, Monoclonal; Diabetes Mellitus, Experimental; Fingolimod Hydrochloride; Graft Rejection; Graft Survival; Immunosuppressive Agents; Indoles; Islets of Langerhans Transplantation; Lymphangiogenesis; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Propylene Glycols; Pyrroles; Sphingosine; Sunitinib; T-Lymphocytes; Transplantation Tolerance; Transplantation, Homologous; Vascular Endothelial Growth Factor Receptor-3 | 2011 |
FTY720-loaded poly(DL-lactide-co-glycolide) electrospun scaffold significantly increases microvessel density over 7 days in streptozotocin-induced diabetic C57b16/J mice: preliminary results.
Topics: Animals; Automation; Biocompatible Materials; Diabetes Mellitus, Experimental; Drug Delivery Systems; Extracellular Matrix; Fingolimod Hydrochloride; Hypoxia; Image Processing, Computer-Assisted; Immunosuppressive Agents; Lactic Acid; Male; Materials Testing; Mice; Mice, Inbred C57BL; Microvessels; Nanofibers; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Propylene Glycols; Sphingosine; Streptozocin; Tissue Scaffolds | 2011 |
Immunosuppression with FTY720 and cyclosporine A inhibits rejection of adult porcine islet xenografts in rats.
Topics: Animals; Blood Cell Count; Cyclosporine; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Female; Fingolimod Hydrochloride; Graft Rejection; Immunosuppression Therapy; Immunosuppressive Agents; Islets of Langerhans Transplantation; Isoantibodies; Mice; Mice, Nude; Propylene Glycols; Rats; Rats, Inbred Lew; Sphingosine; Swine; Transplantation, Heterologous | 2003 |
Islet allograft survival in nonhuman primates immunosuppressed with basiliximab, RAD, and FTY720.
Topics: Animals; Antibodies, Monoclonal; Basiliximab; Diabetes Mellitus, Experimental; Everolimus; Fingolimod Hydrochloride; Graft Rejection; Graft Survival; Immunosuppressive Agents; Islets of Langerhans; Islets of Langerhans Transplantation; Macaca fascicularis; Propylene Glycols; Recombinant Fusion Proteins; Sirolimus; Sphingosine | 2004 |
Long-term effect of FTY720 on lymphocyte count and islet allograft survival in mice.
Topics: Animals; Blood Glucose; Cell Movement; Diabetes Mellitus, Experimental; Disease Models, Animal; Fingolimod Hydrochloride; Graft Survival; Immunosuppressive Agents; Islets of Langerhans Transplantation; Lymphocyte Count; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Propylene Glycols; Random Allocation; Sphingosine; Time Factors | 2007 |
Immunosuppressive effect of FTY 720 on rat pancreas allograft.
Topics: Animals; Apoptosis; Diabetes Mellitus, Experimental; Duodenum; Fingolimod Hydrochloride; Graft Survival; Immunosuppressive Agents; Male; Pancreas Transplantation; Propylene Glycols; Rats; Rats, Inbred Lew; Rats, Inbred Strains; Sphingosine; Transplantation, Homologous | 1998 |
FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory.
Topics: Animals; Antibodies, Viral; Autoimmune Diseases; Cell Movement; Cytotoxicity, Immunologic; Diabetes Mellitus, Experimental; Edema; Fingolimod Hydrochloride; Hypersensitivity, Delayed; Immunologic Memory; Immunosuppressive Agents; Lymphocyte Activation; Lymphocyte Count; Lymphocytic choriomeningitis virus; Lymphopenia; Mice; Mice, Inbred C57BL; Mice, Transgenic; Propylene Glycols; Sphingosine; T-Lymphocytes, Cytotoxic | 2000 |
Long-term islet graft survival in streptozotocin- and autoimmune-induced diabetes models by immunosuppressive and potential insulinotropic agent FTY720.
Topics: Animals; Autoimmune Diseases; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Experimental; Fingolimod Hydrochloride; Graft Survival; Immunosuppressive Agents; Insulin; Insulin Secretion; Islets of Langerhans; Islets of Langerhans Transplantation; Male; Mice; Mice, Inbred BALB C; Mice, Inbred CBA; Mice, Inbred NOD; Propylene Glycols; Sphingosine; Time Factors | 2002 |